MARK4 controls ischaemic heart failure through microtubule detyrosination

Xian Yu,Xiao Chen,Mamta Amrute-Nayak,Edward Allgeyer,Aite Zhao,Hannah Chenoweth,Marc Clement,James Harrison,Christian Doreth,George Sirinakis,Thomas Krieg,Huiyu Zhou,Hongda Huang,Kiyotaka Tokuraku,Daniel St Johnston,Ziad Mallat,Xuan Li
DOI: https://doi.org/10.1038/s41586-021-03573-5
IF: 64.8
2021-05-26
Nature
Abstract:Myocardial infarction is a major cause of premature death in adults. Compromised cardiac function after myocardial infarction leads to chronic heart failure with systemic health complications and a high mortality rate<sup><a href="/articles/s41586-021-03573-5#ref-CR1">1</a></sup>. Effective therapeutic strategies are needed to improve the recovery of cardiac function after myocardial infarction. More specifically, there is a major unmet need for a new class of drugs that can improve cardiomyocyte contractility, because inotropic therapies that are currently available have been associated with high morbidity and mortality in patients with systolic heart failure<sup><a href="/articles/s41586-021-03573-5#ref-CR2">2</a>,<a href="/articles/s41586-021-03573-5#ref-CR3">3</a></sup> or have shown a very modest reduction of risk of heart failure<sup><a href="/articles/s41586-021-03573-5#ref-CR4">4</a></sup>. Microtubule detyrosination is emerging as an important mechanism for the regulation of cardiomyocyte contractility<sup><a href="/articles/s41586-021-03573-5#ref-CR5">5</a></sup>. Here we show that deficiency of microtubule-affinity regulating kinase 4 (MARK4) substantially limits the reduction in the left ventricular ejection fraction after acute myocardial infarction in mice, without affecting infarct size or cardiac remodelling. Mechanistically, we provide evidence that MARK4 regulates cardiomyocyte contractility by promoting phosphorylation of microtubule-associated protein 4 (MAP4), which facilitates the access of vasohibin 2 (VASH2)—a tubulin carboxypeptidase—to microtubules for the detyrosination of α-tubulin. Our results show how the detyrosination of microtubules in cardiomyocytes is finely tuned by MARK4 to regulate cardiac inotropy, and identify MARK4 as a promising therapeutic target for improving cardiac function after myocardial infarction.
multidisciplinary sciences
What problem does this paper attempt to address?
### What problems does this paper attempt to solve? This paper aims to explore the role of Microtubule - Affinity Regulating Kinase 4 (MARK4) in the regulation of cardiac function after myocardial infarction (MI), especially its mechanism of regulating cardiomyocyte contractility through microtubule detyrosination. Specifically, the study attempts to answer the following key questions: 1. **Causes of impaired cardiac function after myocardial infarction**: Myocardial infarction is the leading cause of ischaemic heart disease (IHD) and chronic heart failure, which will lead to a large number of cardiomyocyte deaths and the loss of function of the remaining surviving cells. Effective treatment strategies are crucial for improving the recovery of cardiac function after myocardial infarction. 2. **Limitations of existing drug therapies**: Currently available inotropic therapies for enhancing myocardial contractility are associated with high morbidity and mortality when treating patients with diastolic heart failure, or only show a very limited risk - reduction effect. Therefore, new drug classes need to be developed to improve cardiomyocyte contractility. 3. **The role of microtubule detyrosination**: Microtubule detyrosination is an emerging and important mechanism that can regulate the contractility of cardiomyocytes. Previous studies have shown that inhibiting microtubule detyrosination can improve the contractility of failing cardiomyocytes. However, its specific regulatory mechanism is still unclear. 4. **The role of MARK4 in cardiomyocytes**: Although MARK4 is known to be expressed in the heart, its specific function in cardiomyocytes has not been fully studied. This paper verifies experimentally whether MARK4 affects the contractility of cardiomyocytes by regulating microtubule detyrosination. ### Main findings - **Effect of MARK4 deficiency on left ventricular ejection fraction (LVEF)**: The study found that in a mouse model, MARK4 gene knockout (Mark4 - / -) significantly limited the decrease in left ventricular ejection fraction after acute myocardial infarction without affecting the infarct area or cardiac remodeling. - **Mechanism by which MARK4 regulates cardiomyocyte contractility**: Further studies have shown that MARK4 promotes the phosphorylation of microtubule - associated protein 4 (MAP4), thereby promoting Vasohibin 2 (VASH2) to access microtubules for α - tubulin detyrosination, and then regulates the contractility of cardiomyocytes. - **MARK4 as a potential therapeutic target**: The research results indicate that MARK4 is a promising druggable target that can be used to develop new therapies for improving cardiac function after myocardial infarction. In conclusion, this study reveals the important role of MARK4 in the regulation of cardiac function after myocardial infarction and provides a theoretical basis for the development of new treatment strategies.